Bicara Therapeutics Inc [BCAX] stock prices are up 3.40% to $12.16 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BCAX shares have gain 19.80% over the last week, with a monthly amount drifted -1.94%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bicara Therapeutics Inc [NASDAQ: BCAX] stock has seen the most recent analyst activity on April 17, 2025, when Wells Fargo initiated its Underweight rating and assigned the stock a price target of $8. Previously, Wedbush started tracking the stock with Outperform rating on February 06, 2025, and set its price target to $31. On December 06, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $42 on the stock. Rodman & Renshaw started tracking the stock assigning a Buy rating and suggested a price target of $48 on November 05, 2024. TD Cowen initiated its recommendation with a Buy. Stifel started tracking with a Buy rating for this stock on October 08, 2024, and assigned it a price target of $47. In a note dated October 08, 2024, Morgan Stanley initiated an Overweight rating and provided a target price of $35 on this stock.
The stock price of Bicara Therapeutics Inc [BCAX] has been fluctuating between $8.91 and $28.09 over the past year. Currently, Wall Street analysts expect the stock to reach $48 within the next 12 months. Bicara Therapeutics Inc [NASDAQ: BCAX] shares were valued at $12.16 at the most recent close of the market. An investor can expect a potential return of 294.74% based on the average BCAX price forecast.
Analyzing the BCAX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.13, Equity is -0.27 and Total Capital is -0.17. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.06 points at the first support level, and at 9.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.74, and for the 2nd resistance point, it is at 13.33.
Ratios To Look Out For
It’s worth pointing out that Bicara Therapeutics Inc [NASDAQ:BCAX]’s Current Ratio is 27.93. As well, the Quick Ratio is 27.93, while the Cash Ratio is 27.22.
Transactions by insiders
Recent insider trading involved Meisner Lara, Chief Legal Officer, that happened on Mar 14 ’25 when 79146.0 shares were sold. Officer, LARA S. MEISNER completed a deal on Mar 14 ’25 to buy 79146.0 shares. Meanwhile, Director RA CAPITAL MANAGEMENT, L.P. bought 1.83 million shares on Sep 16 ’24.
